Deciphering the mystery of thalidomide teratogenicity

Congenital Anomalies

Volumn 52, Issue 1, 2012, Pages 1-7

  Ito, Takumi ^a   Handa, Hiroshi ^a  

^a TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Cereblon; Ferrite glycidyl methacrylate beads; Teratogenicity; Thalidomide; Ubiquitin

Indexed keywords

DNA BINDING PROTEIN; FERRITE; FIBROBLAST GROWTH FACTOR 10; FIBROBLAST GROWTH FACTOR 8; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; THALIDOMIDE; UBIQUITIN PROTEIN LIGASE E3; WNT PROTEIN;

AEROBIC METABOLISM; ANGIOGENESIS; AUTISM; BIRTH DEFECT; CIRCULATION; CONCEPTION; DRUG ACTIVITY; DRUG BINDING; DRUG EFFECT; DRUG EXPOSURE; DRUG MEGADOSE; EMBRYO DEATH; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; LEARNING; LIGAND BINDING; LIMB DEVELOPMENT; LIMB MALFORMATION; MAGNETIC SEPARATION; MEMORY; MENTAL DEFICIENCY; MICROPHTHALMIA; MICROTIA; NONHUMAN; OXIDATIVE STRESS; PHOCOMELIA; PRIORITY JOURNAL; REVIEW; TERATOGENICITY; UBIQUITINATION;

ANIMALS; CHICK EMBRYO; FEMALE; FIBROBLAST GROWTH FACTOR 8; HUMANS; LIMB DEFORMITIES, CONGENITAL; METHACRYLATES; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; OXIDATIVE STRESS; PEPTIDE HYDROLASES; PREGNANCY; TERATOGENS; THALIDOMIDE; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES; ZEBRAFISH;

EID: 84857319432     PISSN: 09143505     EISSN: 17414520     Source Type: Journal    
DOI: 10.1111/j.1741-4520.2011.00351.x     Document Type: Review

References (50)

1. Ando Y, Fuse E, Figg WD. 2002. Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res 8:1964-1973.
2. Angers S, Li T, Yi X, MacCoss MJ, Moon RT, Zheng N. 2006. Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery. Nature 443:590-593.
3. Bartlett JB, Dredge K, Dalgleish AG. 2004. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 4:314-322.
4. Bauer KS, Dixon SC, Figg WD. 1998. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 55:1827-1834.
5. Bedford L, Lowe J, Dick LR, Mayer RJ, Brownell JE. 2010. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov 10:29-46.
6. Brent RL. 1964. Drug testing in animals for teratogenic effects. Thalidomide in the pregnant rat. J Pediatr 64:762-770.
7. Cang Y, Zhang J, Nicholas SA etal. 2006. Deletion of DDB1 in mouse brain and lens leads to p53-dependent elimination of proliferating cells. Cell 127:929-940.
8. Cang Y, Zhang J, Nicholas SA, Kim AL, Zhou P, Goff SP. 2007. DDB1 is essential for genomic stability in developing epidermis. Proc Natl Acad Sci USA 104:2733-2737.
9. Castilla EE, Ashton-Prolla P, Barreda-Mejia E etal. 1996. Thalidomide, a current teratogen in South America. Teratology 54:273-277.
10. Cohen P, Tcherpakov M. 2010. Will the ubiquitin system furnish as many drug targets as protein kinases? Cell 143:686-693.
11. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. 1994. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082-4085.
12. Davies F, Baz R. 2010. Lenalidomide mode of action: linking bench and clinical findings. Blood Rev 24(Suppl 1):S13-S19.
13. Franks ME, Macpherson GR, Figg WD. 2004. Thalidomide. Lancet 363:1802-1811.
14. Groisman R, Polanowska J, Kuraoka I etal. 2003. The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage. Cell 113:357-367.
15. Hakkola J, Pelkonen O, Pasanen M, Raunio H. 1998. Xenobiotic-metabolizing cytochrome P450 enzymes in the human feto-placental unit: role in intrauterine toxicity. Crit Rev Toxicol 28:35-72.
16. Hansen JM, Harris C. 2004. A novel hypothesis for thalidomide-induced limb teratogenesis: redox misregulation of the NF-kappaB pathway. Antioxid Redox Signal 6:1-14.
17. Hansen JM, Gong SG, Philbert M, Harris C. 2002. Misregulation of gene expression in the redox-sensitive NF-kappab-dependent limb outgrowth pathway by thalidomide. Dev Dyn 225:186-194.
18. Higgins JJ, Pucilowska J, Lombardi RQ, Rooney JP. 2004. A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation. Neurology 63:1927-1931.
19. Hohberger B, Enz R. 2009. Cereblon is expressed in the retina and binds to voltage-gated chloride channels. FEBS Lett 583:633-637.
20. Ito T, Ando H, Suzuki T etal. 2010. Identification of a primary target of thalidomide teratogenicity. Science 327:1345-1350.
21. Jin J, Arias EE, Chen J, Harper JW, Walter JC. 2006. A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1. Mol Cell 23:709-721.
22. Jo S, Lee KH, Song S, Jung YK, Park CS. 2005. Identification and functional characterization of cereblon as a binding protein for large-conductance calcium-activated potassium channel in rat brain. J Neurochem 94:1212-1224.
23. Knobloch J, Ruther U. 2008. Shedding light on an old mystery: thalidomide suppresses survival pathways to induce limb defects. Cell Cycle 7:1121-1127.
24. Knobloch J, Shaughnessy JD, Jr, Ruther U. 2007. Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathway. FASEB J 21:1410-1421.
25. Knobloch J, Schmitz I, Gotz K, Schulze-Osthoff K, Ruther U. 2008. Thalidomide induces limb anomalies by PTEN stabilization, Akt suppression, and stimulation of caspase-dependent cell death. Mol Cell Biol 28:529-538.
26. Lee J, Zhou P. 2007. DCAFs, the missing link of the CUL4-DDB1 ubiquitin ligase. Mol Cell 26:775-780.
27. Lee AY, Hsu CH, Wu SH. 2004. Functional domains of Brevibacillus thermoruber lon protease for oligomerization and DNA binding: role of N-terminal and sensor and substrate discrimination domains. J Biol Chem 279:34903-34912.
28. Lewandoski M, Sun X, Martin GR. 2000. Fgf8 signalling from the AER is essential for normal limb development. Nat Genet 26:460-463.
29. Melchert M, List A. 2007. The thalidomide saga. Int J Biochem Cell Biol 39:1489-1499.
30. Mellin GW, Katzenstein M. 1962. The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies. N Engl J Med 267:1184-1192.
31. Miller MT, Stromland K. 1999. Teratogen update: thalidomide: a review, with a focus on ocular findings and new potential uses. Teratology 60:306-321.
32. Moon AM, Capecchi MR. 2000. Fgf8 is required for outgrowth and patterning of the limbs. Nat Genet 26:455-459.
33. Nishio K, Masaike Y, Ikeda M etal. 2008. Development of novel magnetic nano-carriers for high-performance affinity purification. Colloids Surf B Biointerfaces 64:162-169.
34. Ohtake F, Baba A, Takada I etal. 2007. Dioxin receptor is a ligand-dependent E3 ubiquitin ligase. Nature 446:562-566.
35. Ohuchi H, Nakagawa T, Yamamoto A etal. 1997. The mesenchymal factor, FGF10, initiates and maintains the outgrowth of the chick limb bud through interaction with FGF8, an apical ectodermal factor. Development 124:2235-2244.
36. Pajni-Underwood S, Wilson CP, Elder C, Mishina Y, Lewandoski M. 2007. BMP signals control limb bud interdigital programmed cell death by regulating FGF signaling. Development 134:2359-2368.
37. Parman T, Wiley MJ, Wells PG. 1999. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med 5:582-585.
38. Petroski MD, Deshaies RJ. 2005. Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 6:9-20.
39. Pickart CM. 2004. Back to the future with ubiquitin. Cell 116:181-190.
40. Sakamoto S, Kabe Y, Hatakeyama M, Yamaguchi Y, Handa H. 2009. Development and application of high-performance affinity beads: toward chemical biology and drug discovery. Chem Rec 9:66-85.
41. Schuler-Faccini L, Soares RC, de Sousa AC etal. 2007. New cases of thalidomide embryopathy in Brazil. Birth Defects Res A Clin Mol Teratol 79:671-672.
42. Sheskin J. 1965. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 6:303-306.
43. Shimizu N, Sugimoto K, Tang J etal. 2000. High-performance affinity beads for identifying drug receptors. Nat Biotechnol 18:877-881.
44. Singhal S, Mehta J, Desikan R etal. 1999. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571.
45. Stephens TD, Fillmore BJ. 2000. Hypothesis: thalidomide embryopathy-proposed mechanism of action. Teratology 61:189-195.
46. Therapontos C, Erskine L, Gardner ER, Figg WD, Vargesson N. 2009. Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proc Natl Acad Sci USA 106:8573-8578.
47. Vargesson N. 2009. Thalidomide-induced limb defects: resolving a 50-year-old puzzle. Bioessays 31:1327-1336.
48. Wittschieben BO, Wood RD. 2003. DDB complexities. DNA Repair (Amst) 2:1065-1069.
49. Zeldis JB, Williams BA, Thomas SD, Elsayed ME. 1999. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 21:319-330.
50. Zhu YX, Braggio E, Shi CX etal. 2011. Cereblon expression is required for the anti-myeloma activity of lenalidomide and pomalidomide. Blood. 118:4771-4779.